Nature Communications (Dec 2019)
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
- Ryota Tamura,
- Masato Fujioka,
- Yukina Morimoto,
- Kentaro Ohara,
- Kenzo Kosugi,
- Yumiko Oishi,
- Mizuto Sato,
- Ryo Ueda,
- Hirokazu Fujiwara,
- Tetsuro Hikichi,
- Shinobu Noji,
- Naoki Oishi,
- Kaoru Ogawa,
- Yutaka Kawakami,
- Takayuki Ohira,
- Kazunari Yoshida,
- Masahiro Toda
Affiliations
- Ryota Tamura
- Department of Neurosurgery, Keio University School of Medicine
- Masato Fujioka
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine
- Yukina Morimoto
- Department of Neurosurgery, Keio University School of Medicine
- Kentaro Ohara
- Department of Pathology, Keio University School of Medicine
- Kenzo Kosugi
- Department of Neurosurgery, Keio University School of Medicine
- Yumiko Oishi
- Department of Neurosurgery, Keio University School of Medicine
- Mizuto Sato
- Department of Neurosurgery, Keio University School of Medicine
- Ryo Ueda
- Department of Neurosurgery, Keio University School of Medicine
- Hirokazu Fujiwara
- Department of Radiology, Keio University School of Medicine
- Tetsuro Hikichi
- OncoTherapy Science, Inc.
- Shinobu Noji
- Division of Cellular Signaling Institute for Advanced Medical Research, Keio University School of Medicine
- Naoki Oishi
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine
- Kaoru Ogawa
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine
- Yutaka Kawakami
- Division of Cellular Signaling Institute for Advanced Medical Research, Keio University School of Medicine
- Takayuki Ohira
- Department of Neurosurgery, Keio University School of Medicine
- Kazunari Yoshida
- Department of Neurosurgery, Keio University School of Medicine
- Masahiro Toda
- Department of Neurosurgery, Keio University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-13640-1
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 11
Abstract
The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resistant tumors.
